In recent years, the fields of fluoropolymers and fluorinated pharmaceuticals have demonstrated unique development trends. Their future prospects have attracted significant attention, influenced by multiple factors such as policies, market demands, and technological innovations.
In the realm of fluoropolymers, the policy guidance is crystal clear. The Industrial Structure Adjustment Guidance Catalog designates special fluorinated monomers like perfluoroolefin ethers, high-quality fluororesins such as polyperfluoroethylene propylene (FEP) and polyvinylidene fluoride (PVDF), high-performance fluororubbers including fluoroether rubber and fluorosilicone rubber, as well as fluorinated lubricating greases as encouraged categories, marking them as key development directions in China's future. National strategies such as "Made in China 2025" also incorporate high-performance materials like fluoropolymers into the category of new materials. For instance, Baotou City plans to establish a complete industrial chain from hydrofluoric acid to tetrafluoroethylene, and then to fluororesins and fluororubbers by 2025. Regions like Hubei, Fujian, and Jiangsu have also prioritized the layout of the fluorochemical industry and fluoropolymer production. On February 18, 2025, Juhua Co., Ltd., a leading enterprise in China's fluorochemical industry, announced its plan to jointly increase capital in Gansu Juhua with its controlling shareholder. The project aims to build production facilities with an annual output of 35,000 tons of tetrafluoropropene (R1234yf), 30,000 tons of polytetrafluoroethylene (PTFE), and 10,000 tons of polyperfluoroethylene propylene (FEP), along with related supporting equipment. These initiatives vividly showcase the flourishing development of the fluoropolymer industry.
Regarding market size projections, the global fluoropolymer market was valued at 7.073 billion US dollars in 2024 and is expected to reach 9.211 billion US dollars by 2031, with a compound annual growth rate (CAGR) of 3.9%. Although China serves as the global hub for the production and consumption of fluoropolymers, accounting for over half of the global production capacity, it faces the issue of an oversupply of low-end products while relying heavily on imports for high-end ones. Nevertheless, driven by the demands of various sub-sectors, fluoropolymers have enormous growth potential. In the fields of new energy and semiconductors, technologies such as lithium battery dry electrodes, anti-corrosion of photovoltaic modules, 5G communication, and AI chip manufacturing have significantly increased the demand for fluoropolymers like PTFE, PVDF, and perfluoroalkoxyalkane (PFA). In environmental protection and data centers, the applications of fluorinated liquids (such as perfluoropolyethers and perfluoroolefins) in data center liquid cooling and semiconductor cleaning are expanding rapidly. Additionally, 3M's withdrawal from the PFAS market has created a window of opportunity for domestic substitution. In high-end manufacturing, the replacement of glass by ETFE in construction and photovoltaic fields, and the irreplaceability of perfluoroether rubber in semiconductor sealing, are driving the demand for high-value-added fluoropolymer products.
Domestic enterprises such as Dongyue Group, Juhua Co., Ltd., and Zhuhai Shineray New Chemical Materials Co., Ltd. have been continuously breaking through technological barriers in areas like PFA, ETFE, and fluorinated liquids, and are taking over overseas production capacity transfers, especially with a strong demand for domestic substitution in the semiconductor field. Moreover, the refrigerant quota system (such as the reduction of R22) is forcing enterprises to shift towards high-value-added products like fluoropolymers. Under the goal of carbon neutrality, the applications of environmentally friendly products such as fluorocarbon coatings and green solvents (hydrofluoroethers) continue to grow. However, high-end products (such as PFA and perfluoroether rubber) are still monopolized by international giants like Chemours and Daikin. Domestic enterprises still need to make breakthroughs in key technologies such as material purity and stability. The demand in some fields (such as refrigerants) is greatly influenced by policies, and they also face competition from high-performance engineering plastics and metal materials.
The field of fluorinated pharmaceuticals is also showing strong development momentum. With the global aging population, increasing health awareness, and growing environmental consciousness, the fluorinated pharmaceutical industry has ushered in broad development prospects. The unique properties of fluorine elements and their compounds endow fluorinated pharmaceuticals with excellent pharmacological activities and bioavailability, making them widely used in various medical fields such as anti-tumor, antibacterial, antiviral, anti-inflammatory, and analgesic treatments. According to the report released by QYResearch, it studies the supply and demand of fluorinated pharmaceuticals in the global and Chinese markets during the "14th Five-Year Plan" period and forecasts the industry's development during the "15th Five-Year Plan" period, focusing on analyzing the production capacity, sales volume, revenue, and growth potential of fluorinated pharmaceuticals in major global regions (historical data from 2019 - 2023, forecast data from 2024 - 2030). Technological innovation, growing market demand, and policy support are the three major driving forces for the development of the fluorinated pharmaceutical industry. Although the fluorinated pharmaceutical industry in China started late, it has developed rapidly. Since the introduction of relevant technologies in the 1980s, it has gradually established its own industrial chain, significantly improving product quality, technological levels, and market competitiveness. Domestic policies provide support in terms of tax incentives, R&D investment, and market access, stimulating enterprises' innovation vitality and market competitiveness.
Overall, fluoropolymers will maintain steady growth in fields such as new energy, semiconductors, and environmental protection, with high-end development and domestic substitution being the core directions. Fluorinated pharmaceuticals will also continue to expand their market scale with the development of the global pharmaceutical market and their own unique advantages. However, both industries face challenges such as technological breakthroughs and market competition during their development. Enterprises need to constantly innovate and seize market opportunities to achieve better development.
